Vagus Stimulation in Female Long COVID Patients.

Not Applicable

Recruiting

• Conditions: Post-COVID Syndrome; Post COVID-19 Condition; Post COVID Condition; Vagus Nerve Diseases; Long COVID; Post-COVID-19 Syndrome; Long Covid19

• Registration Number: NCT05918965
• Lead Sponsor: Medical University of Vienna

Brief Summary

The aim of the present pilot study is to investigate the acceptance, feasibility and implementation of the vagus nerv stimulation in Long COVID patients. Additionally, the effects on parameters of the autonomic nervous system as well as on symptoms of Long COVID will be described in a pre/post comparison.

For this purpose, a total of 45 female Long COVID patients will participate in the randomized controlled pilot study. Patients will perform auricular vagus stimulation daily for 12 weeks. The patient collective will be randomized into three groups (A: 10 hertz, B: 25 hertz, C: 2 hertz=control group).

If appropriate results are obtained, further adequately powered intervention studies are planned.

Detailed Description

Patients start on day 0, when the first assessment takes place. This consists of a medical diagnostic interview and sociodemographic, anthropometric, medical and functional data are collected (for a detailed description, see chapter 5. Statistics). Subsequently, the patients fill out the given questionnaires (paper/pencil version), which are then evaluated. Subsequently, the test persons are trained by a doctor how the electrical stimulation works with a demo device. Finally, the device is taken over by the company Schwa-Medico. The whole first assessment lasts about 2 hours and always takes place from 8 a.m. at constant room temperature (22-23 C°).

The outcome parameters are recorded before the start of the vagus nerve stimulation (T0), during the treatment after 4 weeks (T0+4Wo) and after a total of 12 weeks (T0+12Wo) after the end of the therapy. Which assessments are collected at the different time points is listed in the biometry section. The assessments are performed by physicians of the Department of Physical Medicine, Rehabilitation and Occupational Medicine. All assessments take place at relatively the same time, at constant room temperature (22-23 C°). The patients have to appear fasting.

T0: Medical history, examination, randomization, pre-tests, enrollment. T0+4Wo: Intermediate examination T0+12Wo: final examination, post-tests, return of device

This pilot study investigates the acceptability, feasibility, and implementation of the VNS measure in Long COVID patients. In addition, effects on autonomic nervous system parameters (heart rate, blood pressure, rate pressure product, heart rate variability = HRV, cortisol in saliva), on symptoms fatigue, dyspnea as well as health-related quality of life (HRQOL) are described:

Time points: T0, T0+4wk, T0+12wk.

Parameters - collected at relatively the same time each day, at constant room temperature (22-23 C°):

* Documentation of blood pressure and pulse rate: by means of Boso Medicus (Bosch + Sohn GmbH u. Co. KG, Jungingen, Germany), calculation of the so-called "rate pressure-product" (syst. blood pressure x heart rate)

* Heart rate variability

* Salivary cortisol

* Fatigue: Brief Fatigue Inventory (BFI)

* Health-related quality of life (HRQOL): SF-36 (short form) questionnaire instrument

* Dyspnea: Modified Borg Scale

* Sleep: Insomnia Severity Index (ISI)

Study Timeline

• Study Start: 2023-03-22
• Status Verified: 2023-06
• Study First Submitted: 2023-06-20
• Study First Submitted QC: 2023-06-23
• Last Update Submitted: 2023-06-23
• Study First Posted: 2023-06-26
• Last Update Posted: 2023-06-26
• Primary Completion: 2025-03-01
• Study Completion: 2025-03-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 45

Inclusion Criteria

• Female patients with Long COVID (history, physical examination, findings)
• age 18-70 years
• signed informed consent

Exclusion Criteria

• Hearing aid implants (cochlear implants)
• surgical transection of the vagus nerve
• Malignancies
• autoimmune diseases
• orthopedic diseases
• rheumatological diseases
• neurological diseases
• postoperative, fresh injuries to the ear
• febrile diseases
• inflammations
• psychiatric diseases
• pacemakers
• implanted cardioverter and defibrillators (ICDs)
• seizure disorders
• Meniere's disease
• negative experience with electrotherapy
• insufficient knowledge of the German language

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
Heart rate variability	3 times for 12 weeks	20-minute documentation of the heart rate variability with a 24-hour-elektrocardiography

Secondary Outcome Measures

Name	Time	Method
blood pressure and pulse	3 times for 12 weeks	via Boso Medicus plus their mutiplication for the rate-pressure-product
Saliva cortisol	3 times for 12 weeks	in the morning until the latest 10am
Questionnaire Brief Fatigue Inventory (BFI)	3 times for 12 weeks	Fatigue evaluation
Questionnaire Insomnia Severity Index (ISI)	3 times for 12 weeks	Sleep evaluation
Post-COVID-19 Functional Status scale (PCFS)	3 times for 12 weeks	Grade 0-4
Questionnaire Borg-Scale	3 times for 12 weeks	Dyspnea evaluation
Questionnaire Short form (SF)-36	3 times for 12 weeks	Health related quality of life evaluation

Trial Locations

Locations (1)

Department of Physical Medicine, Rehabilitation and Occupational Medicine, Medical University of Vienna; 🇦🇹 Vienna, Austria